A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of sintilimab plus
ramucirumab compared to stand of care first-line chemotherapy in participants with advanced
gastric or esophagogastric adenocarcinoma.